SG11202110990RA - Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease - Google Patents

Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease

Info

Publication number
SG11202110990RA
SG11202110990RA SG11202110990RA SG11202110990RA SG11202110990RA SG 11202110990R A SG11202110990R A SG 11202110990RA SG 11202110990R A SG11202110990R A SG 11202110990RA SG 11202110990R A SG11202110990R A SG 11202110990RA SG 11202110990R A SG11202110990R A SG 11202110990RA
Authority
SG
Singapore
Prior art keywords
antibodies
treating
methods
neurodegenerative disease
modified anti
Prior art date
Application number
SG11202110990RA
Other languages
English (en)
Inventor
Ester Yoles
Berit Olsen Krogh
Allan Jensen
Jan Egebjerg
Carol David
Kuti Baruch
Michal Eisenbach-Schwartz
Original Assignee
Immunobrain Checkpoint Inc
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunobrain Checkpoint Inc, Yeda Res & Dev filed Critical Immunobrain Checkpoint Inc
Publication of SG11202110990RA publication Critical patent/SG11202110990RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202110990RA 2019-04-19 2020-04-19 Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease SG11202110990RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962836247P 2019-04-19 2019-04-19
EP19170438.6A EP3725370A1 (en) 2019-04-19 2019-04-19 Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
PCT/US2020/028900 WO2020215049A1 (en) 2019-04-19 2020-04-19 Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease

Publications (1)

Publication Number Publication Date
SG11202110990RA true SG11202110990RA (en) 2021-10-28

Family

ID=66240002

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110990RA SG11202110990RA (en) 2019-04-19 2020-04-19 Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease

Country Status (14)

Country Link
US (3) US10995141B2 (https=)
EP (2) EP3725370A1 (https=)
JP (2) JP7752050B2 (https=)
KR (1) KR20220002972A (https=)
CN (1) CN114007645B (https=)
AU (1) AU2020257283B2 (https=)
BR (1) BR112021020947A2 (https=)
CA (1) CA3137143A1 (https=)
CL (2) CL2021002735A1 (https=)
IL (1) IL287008A (https=)
MX (1) MX2021012783A (https=)
SG (1) SG11202110990RA (https=)
WO (1) WO2020215049A1 (https=)
ZA (1) ZA202109173B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2942245C (en) * 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CA3208191A1 (en) * 2021-02-14 2022-08-18 Philip James DOLAN III Methods of using antibodies recognizing tau
CN115073599B (zh) * 2021-03-16 2023-04-28 北京天广实生物技术股份有限公司 结合pd-l1的抗体及其用途
WO2024233694A2 (en) * 2023-05-08 2024-11-14 Immunobrain Checkpoint Inc. METHODS FOR REDUCING IgG ANTIBODY TRANSFER FROM MOTHER TO UNBORN BABY DURING IMMUNOTHERAPY

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20040033497A1 (en) 2002-08-13 2004-02-19 Alarcon-Riquelme Marta E. Polymorphisms of PD-1
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
JP5456235B2 (ja) 2003-11-12 2014-03-26 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経変性疾患を治療するためのワクチン及び方法
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
EP2081961A2 (en) 2006-11-15 2009-07-29 The Brigham and Women's Hospital, Inc. Therapeutic uses of tim-3 modulators
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
WO2009094273A2 (en) 2008-01-15 2009-07-30 Yale University Compositions and methods for adoptive and active immunotherapy
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
AU2009324092A1 (en) 2008-12-03 2011-06-23 Genmab A/S Antibody variants having modifications in the constant region
EP3255060A1 (en) * 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
DK2496594T3 (en) 2009-11-06 2018-03-05 The J David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
WO2011112889A2 (en) 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services β-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY
WO2012075291A1 (en) 2010-12-01 2012-06-07 The Children's Hospital Of Philadelphia Compositions and methods for treating foxp3+ treg related diseases
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
CN103547580B (zh) 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
PT2691112T (pt) 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
AU2012294673B2 (en) 2011-08-05 2015-11-26 Bioasis Technologies Inc. p97 fragments with transfer activity
ES2893855T3 (es) 2011-08-11 2022-02-10 Ono Pharmaceutical Co Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20150086584A1 (en) 2012-03-22 2015-03-26 University Of Miami Multi-specific binding agents
AU2013260132B2 (en) 2012-05-08 2017-12-14 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
IN2014KN00920A (https=) 2012-06-21 2015-10-09 Compugen Ltd
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014022332A1 (en) 2012-07-31 2014-02-06 The Brigham And Women's Hospital, Inc. Modulation of the immune response
US9783589B2 (en) 2012-08-13 2017-10-10 Immungene Inc Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014037952A1 (en) 2012-09-10 2014-03-13 Yeda Research And Development Co. Ltd At The Weizmann Institute Of Science Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
HK1213788A1 (zh) 2012-10-12 2016-07-15 布里格姆及妇女医院股份有限公司 免疫應答的增强
US20150359853A1 (en) 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
CN104903349B (zh) * 2012-11-08 2018-10-19 十一生物治疗股份有限公司 Il-6拮抗剂及其应用
WO2014074852A1 (en) 2012-11-09 2014-05-15 President And Fellows Of Harvard College Compositions and methods for modulating an immune response
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
JP2016513098A (ja) 2013-02-07 2016-05-12 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の２−ピロリノドキソルビシン（ｐ２ｐｄｏｘ）
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
CA2902433A1 (en) 2013-03-01 2014-09-04 Astex Pharmaceuticals, Inc. Drug combinations
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
SI2968294T1 (sl) 2013-03-13 2019-08-30 Oncoceutics, Inc. 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo(1,2-A)pirido (4,3-D)pirimidin-5(3H)-on za uporabo pri zdravljenju raka
SG11201507395PA (en) 2013-03-14 2015-10-29 Curadev Pharma Private Ltd Inhibitors of the kynurenine pathway
EP2968525A4 (en) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai MORBUS NEWCASTLE VIRUSES AND USES THEREOF
SG11201506766PA (en) 2013-03-15 2015-09-29 Dana Farber Cancer Inst Inc Therapeutic peptides
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
KR20150130284A (ko) 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
US20140377253A1 (en) 2013-03-15 2014-12-25 Abbvie Biotherapeutics Inc. Fc variants
WO2014161509A1 (en) 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
WO2014183066A2 (en) 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CA2953287A1 (en) 2013-06-19 2014-12-24 Massachusetts Institute Of Technology In vivo targeting of cells with ligand-conjugated particles
US9452217B2 (en) 2013-06-22 2016-09-27 Nitor Therapeutics Methods for potentiating immune response for the treatment of infectious diseases and cancer
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
BR112016000853A2 (pt) 2013-07-16 2017-12-12 Genentech Inc métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
PT3444271T (pt) 2013-08-08 2022-01-05 Inst Nat Sante Rech Med Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
KR20250024106A (ko) 2013-08-22 2025-02-18 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절
AU2013398294A1 (en) 2013-08-22 2016-03-17 The Council Of The Queensland Institute Of Medical Research Immunoreceptor modulation for treating cancer and viral infections
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
EA201690746A1 (ru) 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
CN104558177B (zh) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
WO2015069697A2 (en) 2013-11-05 2015-05-14 Nkt Therapeutics Inc. Combination therapy
WO2015084721A1 (en) 2013-12-02 2015-06-11 Tabaczynski David A Inhibition of isoprenoid biosynthetic pathways to treat autoimmune disorders
US9931347B2 (en) 2013-12-03 2018-04-03 Iomet Pharma Ltd. Pharmaceutical compound
EP3077504B1 (en) 2013-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
IL263466B2 (en) 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
US10835595B2 (en) 2014-01-06 2020-11-17 The Trustees Of The University Of Pennsylvania PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
WO2017042633A2 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CA2942245C (en) 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
PE20170441A1 (es) 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
US10077308B2 (en) * 2016-06-13 2018-09-18 Askgene Pharma Inc. PD-L1 specific monoclonal antibodies for disease treatment and diagnosis
RU2769282C2 (ru) * 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
HRP20210602T1 (hr) * 2016-06-20 2021-05-14 F-Star Delta Limited Vezujuće molekule koje vežu pd-l1 i lag-3
EP3360898A1 (en) * 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
US20200299400A1 (en) * 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP3634485A4 (en) 2017-06-07 2021-07-21 Silverback Therapeutics, Inc. CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
CN109467603B (zh) * 2017-11-14 2020-02-21 拜西欧斯（北京）生物技术有限公司 抗pd-1抗体及其制备方法和应用

Also Published As

Publication number Publication date
KR20220002972A (ko) 2022-01-07
US11732046B2 (en) 2023-08-22
AU2020257283A1 (en) 2021-12-16
US10995141B2 (en) 2021-05-04
CN114007645A (zh) 2022-02-01
US20200332011A1 (en) 2020-10-22
CL2024002016A1 (es) 2024-10-18
AU2020257283B2 (en) 2026-04-02
BR112021020947A2 (pt) 2022-04-05
IL287008A (en) 2021-12-01
US20240052038A1 (en) 2024-02-15
MX2021012783A (es) 2022-02-10
CN114007645B (zh) 2026-03-27
ZA202109173B (en) 2023-04-26
JP2025114621A (ja) 2025-08-05
JP7752050B2 (ja) 2025-10-09
US20210221893A1 (en) 2021-07-22
JP2022529789A (ja) 2022-06-24
EP3955961A4 (en) 2023-06-14
CL2021002735A1 (es) 2022-05-20
EP3955961A1 (en) 2022-02-23
CA3137143A1 (en) 2020-10-22
EP3725370A1 (en) 2020-10-21
WO2020215049A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
HUS2500032I1 (hu) Bispecifikus anti-BCMA X anti-CD3 antitestek és azok alkalmazásai
ZA202109173B (en) Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
IL283530A (en) Bispecific anti-pd-l1/anti-4-1bb antibodies and their uses
ZA202004494B (en) Anti-tmprss2 antibodies and antigen-binding fragments
IL276872A (en) Dosage for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
IL279251A (en) Methods for treating cancer with bispecific antibodies against CD3XMUC16 and antibodies against PD-1
IL276303A (en) Methods of treating cancer with ANTI-PD-1 antibodies
IL275734B (en) Anti-pd-l1 antibodies and uses thereof
IL281449A (en) Anti-ifnar1 antibodies for the treatment of autoimmune diseases
ZA202003858B (en) Monoclonal antibodies and methods for using same
SG11202012148RA (en) Monoclonal antibodies against human tim-3
IL281441A (en) Anti-cxcl13 antibodies for the treatment of autoimmune diseases and cancer
IL266106A (en) Monoclonal antibody and method of use for treatment of lupus
IL277296A (en) Antibodies against PFRH5 and their antigen-binding fragments
GB201911211D0 (en) Monoclonal antibodies against ambra-1
ZA202210284B (en) Anti-trem1 antibodies and related methods
IL308393A (en) Antibodies for the treatment of alpha-synuclein diseases
GB201910138D0 (en) Anti-pd-l1 antibodies
HK40071089A (en) Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
GB201906538D0 (en) Anti-pd-1 antibodies